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Abstract: Atrial ﬁbrillation (AF) is a condition of genuine clinical concern. This arrhythmia 
increases patient morbidity and mortality, most notably due to stroke, thromboembolism and 
heart failure. Consequentially, there is a strong impetus to acquire a greater understanding of 
its natural history and course in order to provide crucial evidence-based treatment and resource 
allocation in the future. The objective of this review article is to present a concise overview of 
the management of AF, with reference to the recent evidence-based National Institute of Clinical 
Excellence (NICE) National Clinical Guidelines for the management of AF. 
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Introduction
Atrial ﬁbrillation (AF) is the most frequently encountered and sustained cardiac ar-
rhythmia in clinical practice, with an overall population prevalence of 0.65% in the 
United Kingdom (Stewart et al 2001). The incidence of AF has a male predisposition, 
affecting men 1.5 times more commonly than women (Benjamin 1994). The prevalence 
of AF is highly age dependent; occurring in less than 1% of the population aged under 
50 and about 10% of those above 80 (Freestone et al 2003). Furthermore, it is pres-
ent in 3%–6% of acute medical admissions (Lip et al 1994). Given an aging general 
population, the predominance of AF among the elderly and the improved survival of 
patients with cardiovascular disease, its frequency is dramatically increasing. 
AF exacts a signiﬁcant clinical burden. For example, AF is an independent predictor 
of mortality and is associated with an odds ratio for death of 1.5 for men and 1.9 in 
women, independent of other risk factors (Benjamin et al 1998). AF increases the risk 
of stroke by 4–5 fold and accounts for 10%–15% of all ischemic strokes and nearly a 
quarter of strokes in patients aged 80 and over (Lip et al 2001, 2005a). Furthermore, 
it is linked to far more severe strokes, with longer hospitalization and higher 30-day 
mortality compared with subjects without AF (Wolf et al 1991; Lin et al 1996). In 
addition, AF increases the development of heart failure and adversely affects quality 
of life, including cognitive function (Freestone et al 2003). 
AF is most commonly classiﬁed according to its temporal pattern (Levy et al 2003). 
Paroxysmal AF is deﬁned as a self-terminating AF episode lasting less than 7 days, 
and usually less than 48 hours. Sustained AF, lasting longer than 7 days and less than 
a year, is classiﬁed as persistent. Where AF persists beyond a year, it is classiﬁed as 
permanent, irrespective of the fact that there may have been temporary resolution after 
cardioversion. Paroxysmal AF may degenerate into more frequent paroxysms, or a 
sustained form of AF, which in turn may degenerate into permanent AF. ‘Lone AF’ 
is largely a diagnosis of exclusion and refers to AF occurring in the absence of con-
comitant cardiovascular disease (eg, hypertension), structural heart disease (normal 
echocardiogram), with a normal ECG and chest X-ray. Vascular Health and Risk Management 2007:3(1) 110
Kakar et al
Given the substantial clinical burden of AF, its increasing 
frequency coupled with considerable health care costs, there 
is a compelling need for clinically directed evidence based 
clinical guidelines to improve its detection and management. 
This requirement is further justiﬁed by the observed wide 
variation in management and disagreement amongst UK 
consultants regarding what is considered to be the optimal 
management strategy for this highly complex condition. 
Guidelines for the management of AF
The National Institute for Clinical Excellence (NICE [www.
nice.org.uk]) is a UK-centered independent organization 
responsible for providing national guidance on the promo-
tion of good health as well as the prevention and treatment 
of ill health. NICE commissioned the National Collaborating 
Centre for Chronic Conditions, based at the Royal College 
of Physicians, to develop a clinical guideline on AF for use 
in the NHS in England and Wales. This guideline offers 
clinical advice for the management of AF, based on the 
best-published evidence and expert consensus taking into 
account both patient choice and detailed cost efﬁcacy analy-
sis. Furthermore, the guideline highlights key priorities for 
implementation. In this article, we present a brief overview of 
some of the key recommendations made in this document. 
Diagnosis of atrial ﬁbrillation 
The most common presenting symptoms of AF are dyspnea, 
palpitations, chest pain, dizziness, and fatigue (Levy et al 
1999). In patients presenting with these symptoms, manual 
pulse palpation may determine the presence of an irregular 
pulse that warrants further investigation using a 12-lead 
ECG. The use of transthoracic echocardiography (TTE) 
should be limited to those in whom it is important for long-
term management, such as younger patients, those being 
considered for a rhythm control strategy, those in whom the 
probability of underlying structural heart disease is high and 
where clinical risk stratiﬁcation for antithrombotic therapy 
is needed. Where diagnostic uncertainty remains in patients 
with suspected but undiagnosed PAF, 24-hour monitoring 
should be used if symptomatic paroxysms occur less than 24 
hours apart. An event recorder should be reserved for where 
the paroxysms occur more than 24 hours apart. 
Treatment of atrial ﬁbrillation
Changing trends
The treatment of AF has undergone a paradigm shift over the 
last decade. The traditional strategy of predominant rhythm 
control has been challenged by recent data comparing this to 
a more conservative rate control strategy. Results of the ﬁve 
primary rate versus rhythm control trials have shown that rate 
control is a non-inferior strategy to rhythm control in terms 
of mortality (Hohnloser et al 2001; Van gelder et al 2002, 
Wyse et al 2002; Carlsson et al 2003; Opolski et al 2003) or 
quality of life outcomes (Gronefeld et al 2003). However, in 
the largest of these studies (Wyse et al 2002), mortality was 
found to be higher for rhythm control in those with coronary 
heart disease, those without heart failure and those aged over 
65 years old. In an additional rate versus rhythm control 
study by Okcun et al (2004), rhythm control was found to 
be preferable among patients with heart failure and dilated 
cardiomyopathy. However, there was signiﬁcant variation in 
the duration, intensity and quality of anticoagulation in the 
rhythm control arm of this study that may have affected the 
incidence of stroke and thromboembolism. 
The AFFIRM study suggested that whilst the strategy of 
rate control was associated with a trend to reduced mortality 
compared with rhythm control, subgroup analyses showed that 
actually successfully achieving sinus rhythm is associated with 
reduced mortality, which was offset by an increased mortality 
with antiarrhythmic drug and digoxin usage (Wyse et al 2002; 
Corley et al 2004). Of note, anticoagulation usage was an inde-
pendent predictor of improved survival (Corley et al 2004).
The strategies for rate control and rhythm control incor-
porate different pharmacological regimes. Analysis of the 
available evidence demonstrates that different situations 
may warrant adoption of either rate control or rhythm con-
trol strategy. A primary rate control strategy should be the 
preferred initial option in patients with persistent AF over 65 
years, coronary artery disease, those with contraindications 
to antiarrhythmic drugs, patients unsuitable for cardioversion 
and among patients without congestive heart failure. 
In contrast, a primary rhythm control strategy should be 
the preferred initial option in the following patients with per-
sistent AF: those who are symptomatic, younger, presenting 
for the ﬁrst time with lone AF, those with AF secondary to 
a treated/corrected precipitant and in those with congestive 
heart failure. The potential advantages and disadvantages of 
each strategy should be explained to patients. A section of 
patients with AF, who are resistant to the above management, 
may beneﬁt from interventional techniques such as pulmo-
nary vein isolation (PVI) or a surgical Maze procedure.
Rhythm control: the role of cardioversion
Rhythm control may include electrical (ECV) and pharma-
cological (PCV) cardioversion, as well as the use of surgical Vascular Health and Risk Management 2007:3(1) 111
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atrial debulking (Maze) and catheter ablation (eg, pulmonary 
PVI). No difference has been found in rates of successful 
cardioversion or in the risk of thromboembolism and stroke 
between electrical cardioversion (ECV) and PCV as the initial 
treatment strategy (Valencia et al 2002). 
In prolonged cases of AF, ECV is the preferred option 
based on clinical experience and current clinical practice, 
whereas within 48 hours of onset, either pharmacological 
or electrical cardioversion could be performed. Whilst ini-
tial cardioversion is successful in achieving sinus rhythm 
in the majority, approximately 50% of patients are back 
in AF by one year (Lim et al 2004). Patients considered 
most likely to successfully cardiovert and maintain sinus 
rhythm are those with persistent AF of shorter duration 
(onset <12 months), those without underlying structural 
heart disease or AF secondary to a precipitant (eg, treated 
thyroid disease, fever) that has been treated. Hence, careful 
consideration should be made for the presence of coexist-
ing factors that inﬂuence success. For example, a history 
of recurrent AF (Dmochowska-Perz et al 2002), chronic-
obstructive pulmonary disease (Okcun et al 2002), heart 
failure (Okcun et al 2002) and cardiomegaly (Galperin 
et al 2003) has been found to be associated with reduced 
cardioversion success. 
The maintenance of sinus rhythm post cardioversion is 
notoriously difﬁcult and the treatments consistently inﬂuenc-
ing procedural success are limited. Consensus favors initial 
beta-blocker therapy followed by sotalol or ﬂecanide in 
resistant cases (after ensuring good left ventricular function) 
and amiodarone as the ﬁnal resort for patients that require 
antiarrythmic drugs post cardioversion.
Management strategies
Since atrial ﬁbrillation is classiﬁed according its duration of 
onset, management strategies will differ based on the time-
span of existence of AF. It can be seen from above that in 
general, patients who have AF of less than 1 year duration can 
be considered for cardioversion and have the highest chance 
of remission, in contrast to patients whose AF has lasted 
more than 1 year. The aim of treatment in these patients is to 
minimize symptoms and achieve adequate rate control. 
Digoxin has traditionally been used for rate control; 
however it is has limited efﬁcacy in hyperadrenergic states 
and with exercise (David et al 1979). Beta-blockers (Farshi 
et al 1999) and calcium antagonists (Maragno et al 1988) 
control exertional heart rate much more efﬁciently. Where 
required a combination treatment with atenolol and digoxin 
appears to be more effective than beta-blocker alone. Thus, 
evidence suggests that in patients requiring rate control, the 
ﬁrst line of treatment should be beta-blockers or calcium 
antagonists with digoxin reserved for use in more sedentary 
patients (Li-Saw-Hee et al 1998).
When atrial ﬁbrillation is paroxysmal, its management 
can be quite challenging. The aim of treatment is to reduce 
AF frequency, prevent complications and alleviate symptoms 
during the paroxysm itself. The ratio of asymptomatic versus 
symptomatic episodes can be highly variable and may be as 
high as 12:1 (Page et al 1994). Hence, treatment needs to be 
highly tailored to the individual patient and may vary depend-
ing on the frequency of paroxysms. Studies have evaluated 
different regimes of pharmacological therapy for PAF and 
found comparative efﬁcacy with standard beta-blockers and 
sotalol (Steeds et al 1999). Amiodarone (Roy et al 2000; Ko-
chiadakis et al 2004), in has been shown to be superior to all 
other agents (including class 1c agents); however, its efﬁcacy 
is offset by its side- effect proﬁle. Selected patients may be 
suitable for domiciliary self-treatment, using the so-called 
“pill in the pocket approach (Alboni et al 2004). Selection for 
this approach is critically important: these patients should be 
generally well educated, without evidence of coexistent left-
ventricular dysfunction, valvular or ischemic heart disease 
and have infrequent episodes of paroxysmal AF. 
For the hemodynamically compromised AF patient, treat-
ment strategies should be in accordance with resuscitation 
council guidelines with the aim being to re-establish circula-
tion while acknowledging the potential risks of inadequate 
thromboprophylaxis. ECV is indicated irrespective of the 
duration of AF (Michael et al 1999). Intravenous amiodarone 
may be used where delays in ECV are expected. Importantly, 
in patients with known Wolf-Parkinson-White syndrome, 
AV nodal blocking drugs should be avoided.
AF is an important postoperative complication as it signiﬁ-
cantly increases both morbidity (eg, longer hospitalization) and 
mortality (Almassi et al 1997). It occurs in approximately 33% 
of patients post-coronary heart surgery (Vecht et al 1980). One 
major meta-analysis (Crystal et al 2003) helped clarify the util-
ity of varying medical treatments, and found that for patients 
undergoing cardiothoracic surgery, prophylactic administra-
tion of amiodarone, standard beta-blockers and sotalol were all 
justiﬁed in preventing post-operative AF in high-risk patients. 
Evidence in favor of the rate-limiting calcium antagonist dil-
tiazem was extracted from additional studies (Seitelberger et al 
1994). Indeed, rhythm control has been shown to be superior 
to rate control in maintenance of sinus rhythm and decreas-
ing length of hospital stay among patients with postoperative 
AF (Lee et al 2003). Where AF occurs post operatively with Vascular Health and Risk Management 2007:3(1) 112
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patients undergoing non-cardiothoracic surgery, the treatment 
should be similar to that of acute AF.
Failed medical treatment, pre-excitation syndromes, 
poorly controlled symptomatic are all indications for non-
medical interventions in AF. Various treatments including 
PVI (Wazni et al 2005), pacemaker therapy (Levy et al 1999), 
arrhythmia surgery (Kawaguchi et al 1996), atrioventricular 
(AV) junction catheter ablation (Ueng et al 2001), and atrial 
deﬁbrillators (Ricci et al 2004) have variable beneﬁt in these 
patients. Of course, all interventions have inherent procedural 
risks. AV junction ablation mandates the implantation of a 
permanent pacing system. The complications of PVI are not 
insigniﬁcant and include pulmonary vein stenosis. Also, the 
incidence of recurrence of asymptomatic AF post procedures 
is unknown and raises the dilemma of adequate anticoagu-
lation. The recent NICE guidelines have not given speciﬁc 
guidance regarding the use of these procedures. However, 
NICE acknowledges their increasing role in AF manage-
ment. The reasons for referral for specialist intervention or 
continued drug use should be explained and discussed with 
the patient. 
Antithrombotic therapy in AF
The principal aim of antithrombotic therapy in AF is the pre-
vention of ischemic stroke and other thromboembolic events. 
In prevention of stroke, there is overwhelming evidence from 
randomized trials and systematic reviews to suggest beneﬁt 
of thromboprophylaxis in patients with AF (Lip et al 2005, 
Hart et al 1999). 
Compared with placebo, warfarin reduces the risk of 
ischemic stroke and systemic embolism by two-thirds (Hart 
et al 1999, Benavente et al 2003). When compared with 
antiplatelet therapy, adjusted-dose warfarin leads to a 36% 
relative risk reduction in ischemic stroke (Hart et al 1999). 
In contrast, aspirin results in a 22% risk reduction in prevent-
ing ischemic stroke among patients with AF, compared with 
controls (Hart et al 1999). This result is largely driven by 
the Stroke Prevention in AF (SPAF-1) clinical trial, where 
aspirin was more effective in reducing non-disabling strokes 
but did not reduce severe or recurrent strokes in those aged 
75 and over (SPAF study 1991). 
Anticoagulation for persistent AF depends on the adop-
tion of either a rate-control or rhythm-control treatment 
strategy. Where a rhythm-control treatment strategy is 
chosen, antithrombotic therapy is needed to prevent acute 
stroke or other thromboembolic events occurring during or 
shortly after cardioversion. It is well accepted that patients 
should maintain therapeutic anticoagulation (INR 2.0–3.0) 
with warfarin for a minimum of 3 weeks pre-cardioversion 
(Collins et al 1995; Klein et al 2001) and for a minimum of 
4 weeks post cardioversion. In acute cases where cardiover-
sion cannot be postponed, heparin should be administered, 
cardioversion performed, and warfarin be administered for 
at least four weeks post cardioversion. The use of trans-
oesophageal echocardiography may help exclude a left 
atrial thrombus and thus facilitate acute cardioversion where 
adequate pre-procedure anticoagulation was not possible 
(Klein et al 2001).
Data from the rate versus rhythm-control trials sug-
gest that consideration should be given towards long-term 
anticoagulation in patients at high risk of stroke and AF 
recurrence. This is particularly important as there may be 
frequent asymptomatic AF recurrences that can lead to 
thromboembolism in the presence of risk factors (Wyse et al 
2002; Corley et al 2004; Lim et al 2004).
Among patients with permanent AF, adjusted-dose war-
farin is again the most effective treatment aiming for a target 
international normalized ratio (INR) of 2.5 (range 2.0–3.0). 
Where warfarin is inappropriate, aspirin (EAFT 1993; Hart 
et al 1999; Lip et al 2005) should be administered at 75–300 
mg/day. Aspirin should not be co-administered with warfarin 
as it provides no additional thromboprophylactic beneﬁt 
and may in fact be harmful (Lechat et al 2001). There is not 
enough evidence at the moment to recommend combination 
antiplatelet agents for AF. Of note, a recent large clinical trial 
found anticoagulation to be superior to aspirin-clopidogrel 
combination therapy for stroke prevention in AF (ACTIVE, 
Lancet 2005).
The effectiveness of anticoagulation in reducing the rate 
of ischemic stroke is similar for patients with either parox-
ysmal or permanent AF (Van walraven et al 2002). Patients 
with paroxysmal AF have an annual stroke rate similar to 
permanent AF (3.3%) (Lin et al 1996). Paroxysmal AF pa-
tients also frequently have asymptomatic recurrences, and 
thus, they are exposed to the risk of recurrent AF without 
recognition. Anticoagulation for paroxysmal AF should not 
be based on the frequency or duration of paroxysms but on 
appropriate risk stratiﬁcation, as for permanent AF.
The onset of AF is associated with a cluster of thrombo-
embolic events (Wolf et al 1983), but the development of 
intra-atrial thrombi, and the immediate risk of thromboem-
bolism, is perceived to be minimal within the ﬁrst 48 hours. 
Thus, in patients presenting with AF, a clear history of onset 
is necessary in order to guide appropriate antithrombotic 
therapy and cardioversion. Common clinical practice is that 
cardioversion may be safely performed without the need Vascular Health and Risk Management 2007:3(1) 113
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for oral anticoagulation if AF duration is clearly <48 hours 
(Singer et al 2004). 
Secondary prevention of stroke is also well established 
with warfarin (EAFT 1993) However in cases of an acute 
stroke, assessment of the risk from hemorrhagic transfor-
mation in patients with large cerebral infarcts needs to be 
made. There is uncertainty about the optimal timing of 
administration of anticoagulants following acute stroke. 
Patients with AF can not only have thromboembolic stroke 
but also develop lacunar strokes secondary to hypertension 
and other comorbidities, and in such cases, warfarin is less 
effective (Evans et al 2001). There are little data available 
to assess the risks and beneﬁts of warfarin administration in 
the setting of acute stroke and AF. Once cerebral imaging 
has excluded hemorrhage, antithrombotic therapy could 
be commenced within two weeks after a small stroke or 
transient ischemic attack (TIA). In patients with AF who 
have had a large infarction or uncontrolled hypertension, 
antithrombotic therapy should be delayed until at least 2 
weeks after the stroke. 
Practical aspects of anticoagulation
The increasing use of oral anticoagulation therapy as 
thromboprophylaxis in AF has encouraged a move towards 
“point-of-care” (POC) and patient self-monitoring. POC for 
INR testing reduces INR waiting time (Murray et al 2004). 
Self-monitoring is shown to be safe and effective in a UK 
population (Fitzmaurice et al 2005). Patients undertaking 
anticoagulation self-monitoring should be trained by a com-
petent healthcare professional and remain in contact with a 
named clinician. 
Despite clear guidelines, warfarin is underused, with a 
prescription rate of only 15%–44% among eligible patients 
(Bungard et al 2000; Fang et al 2004). Physician perceptions 
of risk beneﬁt are not always reliable and bleeding risks are 
often overestimated (Bungard et al 2000). Elderly patients 
are often suboptimally treated, despite the fact that this age 
group is most likely to beneﬁt from anticoagulation. A careful 
assessment of risk beneﬁt ratio, especially among the elderly, 
should be ascertained rather than simply relying on age or 
physician preference alone.
Improved efforts at risk stratiﬁcation for thromboprophy-
laxis would help target “high risk” subjects for anticoagula-
tion. However, there is variation between the various risk 
stratiﬁcation criteria as well as inconsistencies between the 
published risk stratiﬁcation schema (Lip and Boos 2005). 
For example, the initial joint ACC/AHA/ESC guidelines in 
2001 (Fuster et al 2001) recommended a risk stratiﬁcation 
schema where any “high risk” factor (previous stroke, TIA, 
embolism; hypertension; heart failure; age >75 years; mitral 
stenosis; prosthetic valve) or >1 “moderate risk” factor (age 
65–75; diabetes; coronary artery disease) merits anticoagu-
lation. Thus, a 45-year-old man with AF and hypertension 
would be recommended warfarin using the 2001 ACC/AHA/
ESC schema, but not by other published risk stratiﬁcation 
schemas. This schema has now been suitably modiﬁed (in 
2006) to recommend anticoagulation for those with high 
risk of stroke such as those with prior thromboembolism and 
rheumatic mitral stenosis and for those patients with more 
than 1 moderate risk factor (age 75 years or greater, hyperten-
sion, HF, impaired LV systolic function diabetes mellitus) 
(Fuster et al 2006). For patients with only one moderate risk 
factor the choice of warfarin versus aspirin must be carefully 
considered in the light of the perceived risk/beneﬁt for the 
individual patient. 
Another well-used and validated system, the CHADS2 
risk stratiﬁcation scheme (Gage et al 2001) gives a numerical 
score to each of ﬁve risk factors (congestive heart failure, 
hypertension, age ≥75 years, diabetes and stroke/TIA, the 
latter receiving a score of 2). The total score (0–6) equates 
to a recognized future stroke risk (where a CHADS2 score of 
0 would deﬁne a person as being at “low” risk (and suitable 
for aspirin) and ≥3 as a “high risk” (and warfarin is recom-
mended). However, AF patients with previous stroke, TIA, 
or thromboembolism are considered to be at high risk of a 
further stroke or thromboembolic event. However using the 
CHADS2, such patients with this risk factor alone would 
only have a total CHADS2 score of 2, which would classify 
them as “moderate’ risk”. 
As a result of these uncertainties, the NICE guidelines has 
recommended an algorithm-based risk stratiﬁcation schema 
(Figure 1), which incorporates data from other previously pub-
lished risk stratiﬁcation schemes and has been shown to be appli-
cable to UK clinical practice. The NICE schema (which is based 
on the Birmingham risk stratiﬁcation schema) has been compared 
with the CHADS2 schema and was found to be comparable for 
predicting stroke and vascular events (Lip et al 2006).
Conclusions
The NICE guidelines for AF management are designed 
to assist in decision-making and are based on current best 
available evidence. In no way are they designed to replace 
clinical judgment and patient choices. Indeed, these guide-
lines are an attempt to ease the burden on physicians and 
hospitals in managing this common yet enigmatic disease. 
The future of AF heralds interesting prospects with novel Vascular Health and Risk Management 2007:3(1) 114
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therapy targeting incidence of AF and improved and newer 
anticoagulation regimes.
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